

List of Contents

1	Introduction	1
1.1	Mycophenolic Acid	1
1.1.1	Chemical Properties.....	2
1.2	Pharmacology of MPA	3
1.2.1	Pharmacokinetics of MPA.....	3
1.2.2	Pharmacokinetic Interactions of MPA.....	8
1.2.3	Clinical Aspects of MPA Pharmacokinetics.....	10
1.2.4	Pharmacodynamics of MPA	13
1.3	Analytical Aspects of MPA Measurement and Its Metabolites	14
1.3.1	Sample Preparation.....	15
1.3.2	Chromatography	15
1.3.3	Stability.....	16
1.3.4	Assays for Determination of MPA and Its Metabolites.....	16
1.4	Pharmacology of Pantoprazole	18
2	Research Objectives.....	21
3	Materials.....	23
3.1	Chemicals	23
3.2	Kits	23
3.3	Consumable Material.....	23
3.4	Hardware and Software	24
3.4.1	Hardware	24
3.4.2	Software.....	25
4	Methods	27
4.1	Quantification of MPA and MPAG in Human Plasma	27
4.1.1	Sample Preparation.....	27
4.2	Measurement of IMPDH Activity	28
4.3	Validation Conditions.....	29
4.3.1	Preparation of Calibration and Quality Control Standards	30
4.3.2	Selectivity	31
4.3.3	Limit of Detection	32
4.3.4	LLOQ	32

4.3.5	Linearity	32
4.3.6	Bias and Precision	33
4.3.7	Carry-Over.....	34
4.3.8	Dilution Integrity	34
4.3.9	Extraction Recovery	35
4.3.10	Method Comparison	35
4.3.11	Stability.....	35
4.4	PK/PD Study about an Interaction of Pantoprazole and Myco-phenolic Acid.....	36
4.4.1	Study Description	36
4.4.2	Inclusion and Exclusion Criteria.....	37
4.4.3	Sample Pre-Treatment and Laboratory Analysis.....	38
4.4.4	Pharmacokinetic and Pharmacodynamic Analysis	39
4.4.5	Data Evaluation and Statistical Analysis	40
4.4.6	Sample Size Calculations	41
4.4.7	Descriptive Analysis.....	42
5	Results.....	43
5.1	Validation of an HPLC-UV Assay for Quantification of MPA and MPAG in Human Plasma	43
5.1.1	Limit of Detection	43
5.1.2	Selectivity	44
5.1.3	Linearity	46
5.1.4	Accuracy.....	49
5.1.5	Carry-Over.....	50
5.1.6	Dilution Integrity	51
5.1.7	Extraction Recovery	51
5.1.8	Method Comparison	52
5.1.9	Stability.....	55
5.2	PK/PD Study about an Interaction of Pantoprazole and Myco-phenolic Acid.....	63
5.2.1	Analytical Aspects of Study Samples Measurement	63
5.2.2	Statistical Considerations for Sample Size Calculation.....	64
5.2.3	Demographics.....	65
5.2.4	Adverse Events.....	67
5.2.5	Pharmacokinetics of MPA	68
5.2.6	Pharmacokinetics of MPAG	80
5.2.7	Pharmacodynamics of MPA	84
6	Discussion	93
6.1	Quantification of MPA and MPAG in Human Plasma.....	93

6.1.1	Sample Preparation.....	95
6.1.2	Chromatographic Conditions.....	95
6.1.3	Validation Parameters.....	99
6.1.4	Method Comparison	102
6.1.5	Stability.....	103
6.1.6	Conclusion and Final Remarks.....	107
6.2	PK/PD Study about an Interaction of Pantoprazole and Myco- phenolic Acid.....	108
6.2.1	Pharmacokinetics of MPA after EC-MPS and MMF Intake	108
6.2.2	Influence of Pantoprazole on MPA Pharmacokinetics	111
6.2.3	Influence of Pantoprazole on MPAG Pharmacokinetics	118
6.2.4	Influence of Pantoprazole on IMPDH Activity	120
6.2.5	Proton Pump Inhibitors and Their Clinical Role in MPA Treatment .	122
6.2.6	Limitations of the PK/PD Study	124
6.2.7	Conclusion and Final Remarks.....	126
7	References.....	129
8	Appendix	147
8.1	Short-Term Stability Analysis of Unprocessed Lithium-Heparin Blood at Room Temperature	147
8.2	Demographics of All Patients in the PK/PD Study to Investigate the Interaction of Pantoprazole and MPA	150
8.3	LMEM Results of the PK/PD Study on the Interaction of Pantoprazole and Mycophenolic Acid.....	151
8.3.1	LMEM Syntax for Evaluation of MPA, MPAG Pharmacokinetics and MPA Pharmacodynamics.....	151
8.3.2	LMEM Output of MPA Pharmacokinetics after MPA±PAN Intake ..	152
8.3.3	LMEM Output of MPAG pharmacokinetics after MPA±PAN Intake	157
8.3.4	LMEM Output of MPA Pharmacodynamics After MPA±PAN Intake	160